Business context and reporting period
Filing identity: The supplied metadata names GPGI, Inc., but this filing is for Roman DBDR Tech Acquisition Corp. (Nasdaq: DBDRU, DBDR, DBDRW), a shell-company SPAC. The summary below reflects the filing itself. It covers the quarter and nine months ended September 30, 2021; the financial statements are unaudited.
The company had not begun operations or generated revenue. Its activity consisted of formation, its 2020 IPO, and seeking a business combination. On April 19, 2021, it agreed to merge with CompoSecure Holdings, L.L.C.; the proposed combined company was expected to be named CompoSecure, Inc.
Financial results and liquidity
| Metric | Reported amount |
|---|---|
| Revenue | None; the company reported no operating revenue. |
| Q3 2021 net income | $176,911, versus a loss of $498,591 from operations. Results included $672,462 of warrant-liability fair-value gain and $3,040 of trust interest, against $498,591 of operating and formation costs. |
| Nine-month 2021 net loss | $12,547,529, including $3,338,138 of operating and formation costs and a $9,283,876 warrant-liability fair-value loss, partly offset by $74,485 of trust interest. |
| Cash flow, nine months | $756,857 used in operating activities; $168,400 provided by financing activities; cash decreased $588,457. |
| September 30 liquidity | $15,158 cash outside the trust; $236,289,574 in trust assets, primarily money-market funds invested in U.S. Treasury securities. Working-capital deficit was $2,247,947, excluding $150,000 of franchise and income taxes payable. |
| Liabilities and redeemable shares | Total liabilities were $47,482,131, including $36,739,038 of warrant liabilities and $8,104,600 of deferred underwriting fees. Class A shares subject to possible redemption were reported as temporary equity of $236,191,200. |
Margins are not meaningful for this pre-combination shell company. The filing reports no long-term debt, but describes related-party advances and potential future working-capital loans. Management said the company did not expect to have sufficient cash to meet needs through the earlier of a business combination or May 10, 2022, raising substantial doubt about its ability to continue as a going concern. This contrasts with the MD&A statement that it did not believe additional funds would be needed for operating expenditures.
Material changes, outlook and risks
- Prior-period restatement: Management restated previously issued financial statements after correcting the classification and carrying value of redeemable Class A shares. The correction moved amounts into temporary equity and affected permanent equity and accumulated deficit; the filing also identifies warrant accounting as a complex-instrument issue.
- Proposed CompoSecure transaction: The agreement described an approximate $853 million equity value. Proposed funding included $130 million of CompoSecure senior exchangeable notes bearing 7% annual interest and $45 million from a private placement of 4.5 million Class A shares at $10 each. The notes would be exchangeable at $11.50 per share. The transaction remained subject to approvals, financing, regulatory and other closing conditions; the filing does not establish that it closed.
- Key transaction conditions included at least $210 million of remaining trust cash plus PIPE proceeds after specified transaction expenses, CompoSecure net indebtedness no greater than $250 million, and at least $5 million of CompoSecure cash. The agreement’s stated outside date was December 31, 2021, with a possible extension to January 31, 2022 for pending antitrust review.
- The SPAC had until May 10, 2022 to complete a business combination or, subject to the charter terms, liquidate and redeem public shares. Redemptions, insufficient financing, failure to meet closing conditions, or inability to complete the deal could affect the transaction and investor recoveries; warrants could expire worthless if no combination occurred.
- Controls: Management concluded disclosure controls were ineffective due to a material weakness in internal control over financial reporting related to complex financial instruments. Management performed additional analysis but gave no assurance remediation would be sufficient.
- Management said COVID-19 could adversely affect the company’s financial position, results or target search, though the impact was not determinable. No legal proceedings were reported. The company stated it had no off-balance-sheet arrangements.
Most important facts for investors to verify
- Confirm the issuer identity: this is Roman DBDR Tech Acquisition Corp., not GPGI, Inc.
- Check the status and final terms of the CompoSecure merger, including closing, redemptions, PIPE funding, exchangeable notes, transaction expenses and any amendments to deadlines or conditions.
- Review the restated financial statements and the accounting treatment and valuation of redeemable shares and warrant liabilities.
- Assess available operating cash, related-party advances, the going-concern warning and the apparent difference between that warning and management’s MD&A liquidity outlook.
- Check whether the material weakness was remediated and whether subsequent filings reported further control issues or financial-statement corrections.